To functionally confirm that our ADAM9-responsive MSNs could indeed be employed across tumor types, we assessed ADAM9-substrate cleavage using conditioned medium collected from different gastrointestinal cancer cell lines (i.e., bladder, colon, duodenum, and esophageal). The gene discussed is ADAM9; the disease is neoplasm.